Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

被引：22
|
作者：
Dal Molin, Graziela Z. [1 ]
Omatsu, Kohei [2 ]
Sood, Anil K. [1 ]
Coleman, Robert L. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, 1155 Herman Pressler Dr,CPB 6-3590, Houston, TX 77030 USA
[2] Canc Inst Hosp, Dept Gynecol, Tokyo, Japan
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2018年 / 10卷
关键词：
BRCA; ovarian cancer; PARP; PARP inhibitors; platinum-sensitive ovarian cancer; rucaparib; Rubraca; RECURRENT EPITHELIAL OVARIAN; RIBOSE POLYMERASE INHIBITOR; PARP INHIBITOR; FALLOPIAN-TUBE; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; PRIMARY PERITONEAL; BRCA2; MUTATIONS; SEROUS OVARIAN;
D O I：
10.1177/1758835918778483
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.
引用
收藏
页数：13
相关论文
共 50 条
  • [31] Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials
    Mustafa, Mus'ab Theeb
    Abushanab, Aws Khalid
    Mousa, Mahmoud Taysir
    Qawaqzeh, Rana Ahmed
    Alakhras, Hamza Muneer
    Othman, Ahmad Sami
    Sa'ed, Ahmad
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (1-2) : 71 - 79
  • [32] Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
    Adrianto, Nicholas
    Mangkuliguna, Ghea
    Tandiono, Eunike Jennifer
    Sibarani, Candra Novi Ricardo
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2024, 63 (05): : 601 - 609
  • [33] Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
    He, Haining
    Zhou, Fei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [34] Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
    Ni, Jing
    Cheng, Xianzhong
    Chen, Jin
    Guo, Wenwen
    Dai, Zhiqin
    ONCOTARGETS AND THERAPY, 2020, 13 : 9857 - 9863
  • [35] PARP INHIBITORS IN OVARIAN CANCER THERAPY
    Pisula, Agata
    Sienicka, Agnieszka
    Dobrowolska-Redo, Agnieszka
    Kacperczyk-Bartnik, Joanna
    Romejko-Wolniewicz, Ewa
    PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (02): : 71 - 74
  • [36] Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
    Saravi, Sayeh
    Alizzi, Zena
    Tosi, Sabrina
    Hall, Marcia
    Karteris, Emmanouil
    CELLS, 2021, 10 (09)
  • [37] PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials
    Quynh, Phan Nguyen Nhu
    Nguyen, Phuong Thi Lan
    Nguyen, Ha Thi
    Phung, Toi Lam
    Nguyen, Danielle TuongVy
    Duong, Khanh Ngoc Cong
    BIOMEDICAL RESEARCH AND THERAPY, 2023, 10 (12): : 6090 - 6102
  • [38] Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer
    Bao, Wanying
    Li, Zhengyu
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 194
  • [39] Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis
    Wang, Jin-feng
    Zhao, Lan-bo
    Bin, Ya-di
    Zhang, Kai-lu
    Sun, Chao
    Wang, Yi-ran
    Feng, Xue
    Ji, Jing
    He, Li-song
    Chen, Fang-yao
    Li, Qi-ling
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [40] The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
    Chen, Ying
    Du, Hui
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 99 : 552 - 560
12345